Świtońska Milena, Jarosz Oliwia A, Szołna-Klufczyńska Dagmara, Sierakowska Katarzyna
Department of Neurosurgery and Neurology, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum, 85-168 Bydgoszcz, Poland.
Faculty of Healths Sciences, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University in Torun, 85-067 Bydgoszcz, Poland.
Biomedicines. 2022 Nov 8;10(11):2856. doi: 10.3390/biomedicines10112856.
For years, the diagnosis of prostate cancer has been understated. Despite the relatively low mortality rate, prostate cancer is still one of the most common neoplasms in men, which proves the need for continuous improvements in the diagnostics of this disease. New biomarkers may address these challenges in the form of extracellular vesicles (EV) secreted by prostate cancer cells. The available literature in the PubMed, SCOPUS, and ResearchGate databases from the last ten years was analyzed using search phrases such as extracellular vesicles, microparticles, microvesicles, cancer biomarkers, and prostate cancer. Then, the research was selected in terms of the size of the tested EVs (the EV medium of 100-1000 nm diameter, was taken into account), the latest versions of the literature were selected and compiled, and their results were compared. The group of extracellular vesicles contain a substantial amount of genetic information that can be used in research on the specificity of prostate cancer and other cancers. So far, it has been shown that EVs produced by PCa cells express proteins specific for these cells, which, thanks to their specificity, can make EV useful biomarkers of prostate cancer. Moreover, the importance of the quantitative release of EV from PCa cells has been demonstrated, which may be necessary to diagnose prostate cancer malignancy. Each method positively correlates with Gleason's results and is even characterized by greater diagnostic sensitivity. Medium extracellular vesicles are a promising research material, and their specificity and sensitivity may allow them to be used in future prostate cancer diagnostics as biomarkers.
多年来,前列腺癌的诊断一直被低估。尽管死亡率相对较低,但前列腺癌仍是男性中最常见的肿瘤之一,这证明了对该疾病诊断方法进行持续改进的必要性。新的生物标志物可能以前列腺癌细胞分泌的细胞外囊泡(EV)的形式应对这些挑战。使用细胞外囊泡、微粒、微囊泡、癌症生物标志物和前列腺癌等搜索词,对过去十年PubMed、SCOPUS和ResearchGate数据库中的现有文献进行了分析。然后,根据测试的细胞外囊泡的大小(考虑直径为100 - 1000 nm的细胞外囊泡介质)选择研究,选择并汇编最新版本的文献,并比较它们的结果。细胞外囊泡群体包含大量可用于前列腺癌和其他癌症特异性研究的遗传信息。到目前为止,已经表明前列腺癌细胞产生的细胞外囊泡表达这些细胞特有的蛋白质,由于其特异性,这些蛋白质可使细胞外囊泡成为有用的前列腺癌生物标志物。此外,已经证明了前列腺癌细胞定量释放细胞外囊泡的重要性,这可能是诊断前列腺癌恶性程度所必需的。每种方法都与 Gleason 结果呈正相关,甚至具有更高的诊断敏感性。中等大小的细胞外囊泡是一种很有前景的研究材料,其特异性和敏感性可能使其在未来用于前列腺癌诊断作为生物标志物。